Nautilus Biotechnology (NAUT) Current Leases (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Current Leases of $4.0 million for Q2 2026, up 3.61% sequentially from $3.9 million in Q1 2026, and down 5.54% YoY from $4.2 million in Q2 2025.
Nautilus Biotechnology (NAUT) Current Leases (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Current Leases for 7 years, with the latest figure at $4.0 million in Q2 2026.
- Quarterly Current Leases fell 5.54% year-over-year to $4.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.0 million (down 5.54% YoY) and the FY2025 annual result came in at $3.8 million, down 6.47% from the prior year.
- Current Leases climbed to $4.0 million in Q2 2026 per NAUT's latest filing, from $3.9 million in the prior quarter.
- Over five years, Current Leases peaked at $4.2 million in Q1 2025 and troughed at $1.5 million in Q1 2022.
- A 5-year average of $3.3 million and a median of $3.7 million in 2024 frame the typical range for Current Leases.
- The sharpest annual moves came in 2022 and 2026: Current Leases surged 419.75% in 2022, then retreated 9.19% in 2026.
- Over 5 years, Current Leases stood at $2.0 million in 2022, then surged by 77.7% to $3.5 million in 2023, then advanced by 15.8% to $4.1 million in 2024, then dropped by 6.47% to $3.8 million in 2025, then gained by 4.15% to $4.0 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $4.0 million, $3.9 million, and $3.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Nautilus Biotechnology | 121.29 Mn | 121.29 Mn | 175,000.00 | 3.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.99 Mn |
| Mar 31, 2026 | 3.85 Mn |
| Dec 31, 2025 | 3.83 Mn |
| Sep 30, 2025 | 4.21 Mn |
| Jun 30, 2025 | 4.23 Mn |
| Mar 31, 2025 | 4.24 Mn |
| Dec 31, 2024 | 4.10 Mn |
| Sep 30, 2024 | 3.96 Mn |
| Jun 30, 2024 | 3.82 Mn |
| Mar 31, 2024 | 3.68 Mn |
| Dec 31, 2023 | 3.54 Mn |
| Sep 30, 2023 | 3.47 Mn |
| Jun 30, 2023 | 3.26 Mn |
| Mar 31, 2023 | 3.07 Mn |
| Dec 31, 2022 | 1.99 Mn |
| Sep 30, 2022 | 1.63 Mn |
| Jun 30, 2022 | 1.56 Mn |
| Mar 31, 2022 | 1.49 Mn |
| Dec 31, 2021 | 970,000.00 |
| Sep 30, 2021 | 314,000.00 |